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imervemion rakes advantage of [he immune sysrem's specificiry, surveillance properties, and memory inducrion. The remark able specificiry of rhe immune system would theoretically allow a more rargeted rherapy with fewer side effeCfs than rhe generalized effect that chemorherapy and radiarion have on all proliferating cells. The abiliry of rhe immune syStem to circulate throughom the body could allow rhe removal of micrometasta ses [hat remain cryptic umil they grow ro clinical significance. 3 In addition, production of a long-lasting memory response would theotetically proteCt against new rumors that mighr arise through [he effect of field cancetization. 4 The growth kinetics of NSCLC makes the disease potentially amenable to immunomodulation. Given the usualla[e presenta [ion of NSCLC, the predominant time course from diagnosis to disease progression is 1 year on average. This interval allows time for standard of care therapy followed by weeks of repeti dve cycles of immunization and evaluation for clinical effect. Because i[ is estimared [hat [here will be > 213,000 new cases of NSCLC this year, predominancly presenting in advanced srages withoUt available cmative therapy, there will be vast opportuni ties for clinical rrials. l More recent data suggest lung cancer, previously thought ro be a reJarively nonimmunogenic rumor, might stimulare [he immune sysrem. To date, [here have been a mulrirude of antigens identified in lung cancer, many of which have been found to be immunogenic in other cancer models. Given rhe growing collection of antigens exptessed in NSCLC, its immune ModLi!ation in NSClC growrh kinetics, and the large numbers of parients affected by the disease, rhis tumor represents an important model for clinical trials in immunotherapy.
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The furure success of any vaccine depends on the exact selec tion of antigens because their inclusion dictates the potential scope of the induced immunity. A NSCLC vaccine will require the inclusion of a diverse collection of antigens because there is variable expression of antigens in individual tumors. Several an tigens, such as Wilm's Tumor Antigen 1 CWTl) and carcinoem bryonic antigen (CEA), have been found to be exptessed in 96% and 70% of NSCLCs, respectively.5,6 Other antigens such as MAGE-A4 and NY-ESO-l have been found ro be expressed in only 28% and 8% of NSCLCs, respectively, and their inclusion in a vaccine might have less of an impact'? Ensuring that specific antigens are not mutually exclusive is also imporranr. Thus, the choice of antigens will be partially dictated by rhe breadth and frequency to which they ate exptessed in individual NSCLCs.
In addirion, tumors have been known ro exhibit porential immune escape mechanisms, including loss of antigens,S,? mu tagenesis of targeted epiropes,IO and downregulation of major hisrocompatibility complex (MHC) molecules. 1 1,12 Given the continuous srate of mutagenesis in cancer cells, the predictable loss of the speciflc targeted antigen, epirope, or MHC haplotype by a NSCLC cell would effectively render it immune ro rhe vaccine's effect, and the tumor would continue ro proliferate. To counteract these pitfalls, ir will be necessary ro incorporare multiple epiropes of several antigens wirh varying MHC haplo type restrictions. Moreover, the vaccine musr elicir potent tissue destructive inflammation. Thus, antigen selection and vaccine delivery are keys ro rhe success of lung cancer vaccines.
One caveat ro the need for inclusion of multiple anrigens in a vaccine formulation concerns rhe idea of epirope spteading. Theoretically, epirope spreading occurs after the initial immune response modulates rhe rumor microenvironmenr to enhance presentation of rumor cell antigens by antigen-ptesenting cells (APCs).13 This broadening of the immune response could srrengthen immunity via rhe divetsification of rhe immune responses to antigens nor incorporared in rhe original vaccine. Generation of epirope spteading underscotes the need for a powerful initial immune response necessary ro cause the inflam mation needed ro activare APCs.
It will be crirical ro selecr antigens rhar have some biologic significance promoting the growrh of the NSCLC cells. Tar gering proreins necessary for cell proliferation or metaStasis would remove the cells with the most aggressive phenotype or, theoterically, creare a situarion in which rhe loss of 1 of the antigens might prevent roral rumor etadication but result in rhe outgrowth of tumor cells with a less aggressive pheno type. 'WTl is a rtanscription facrot fOW1d ro have impo[[ant tumorigenic effects in many tumors and has been found ro be overexptessed in 96% of NSCLCs.5 Addirionally, increases in matrix metalloproreinase 2 in NSCLC cells is seen in patienrs with advanced merastatic disease and mighr represenr an ideal antigen ro pursue. 14 One final consideration of antigen selecrion involves the, changing scope of expressed antigens depending on rumor stage. Cho er al showed the diffetential protein expression of antigens in small-cell lung cancer cells depending on the srage of a patient's cancet. IS Most likely, a sim ilar shifring antigenic reperroire with disease stage is operative in NSCLC as welL Ad dirionally, rhe multiple subclasses ofNSCLC will also dicrate a change in the selected antigens as demonstrated by MAGE-A4, which is expressed more ofren in squamous cell carcinomas than in adenocarcinomas.l 6 The Hnal fOtmulation of a vaccine can be divided into 2 sepa rate components, each wirh significant variables that will influ ence irs potency. First, vaccines typically include full-length copies of the antigen or the individual epirope, described as the minimal sequence necessary to fit inro an MHC groove and induce an immune response. Second, the chosen form of the antigen musr be delivered ro APCs via an immunizarion strategy, usually in the form of free antigen emulsified in adjuvant, whole tumor cell, dendritic cell (DC), viral, or DNA-based methodology.
To minimize the need for antigen discovery and include all relevant antigens by default, whole-cell rumor vaccines have been studied, and clinical rrials have been conducted in parients with NSCLC. Three phase IfII clinical trials have been performed in which the patienr's rumor was resected and transferred with the gene for production of granulocyte-macrophage colony-stimulat ing faCtor (GM-CSF) prior ro immunization, creating a vaccine known as GVAX®.J7·19 Although in early phase, 2 of the studies demonsrrated small bur significanr rumor responses in a minotity of patients who teceived the aurologous rumor cell vaccine. Spe cifically, 2 patienrs exhibired radiologic evidence of rumor regtes sion with durable complete responses (CRs) lasting 6 months ro > 22 months. In addition to the small clinical effect, one of the more pressing limitations of the above-mentioned srudies lies in the difficulty of crearing the vaccine fOt ail enrolled. Although investigators wete able ro generare vaccine fOt 81 %-97% of the enrolled patienrs, the reasons for fuilure were predominantly mi crobiologic contaminarion and insufficient tumor cell numbers. Expanding this vaccine method ro the genetal population will be difficult because it demands colleCtion of rumor tissue that might not be possible wirhoUt increased risk in many patienrs as a resulr of theit comorbidities.
To circumvenr the problem of developing autologous cell based vaccines, rhe identiflcation of broadly expressed ancigens that ate present in NSCLC cells would allow their specific inclusion in an antigen-specific vaccine that could be uniformly manufaCtured. Modern rechniques allow fo~' (he production of antigens in nucleic acid, vital, Ot protein forms capable for long term stotage, thus alleviating production ptoblems.
Human telomerase teverse rranscriprase (TeRT) has been as sociated with NSCLC and tecently, 2 trials have evaluated the ability of subcuraneously injected TeRT pep tides ro induce im mune responses a.nd clinical effecrs. Bolonaki er al vaccinated 22 parienrs with advanced NSCLC with a single pepride subcutane ously, with only minor skin reactions as advetse effects. 20 Pepride specific CTLs were found in 91 % of patienL5 who received rhe full vaccinarion course (n = 11). Compared wirh nonresponders, parients wirh elicired CTLs had a sratisrically significanr longer time to progression (4.2 months vs. 2.3 months; log-rank P = .046) and overall survival (OS; 30 months vs. 4.1 months; P = .012) ar a median follow-up time of 10 months. In a previously published srudy also using a vaccine consisting of subcutaneously injecred TeRT peptides, the only CR was seen in a parient who developed peptide-specific CTLs. 21 In congruence with the pos tulared mechanism of acrion, the inducrion of peptide-specific effector cells is required for production of clinical effect. Improve menr of rhe vaccine's potency is thus critical for development of rherapeutic interventions with berter efficacy.
One of rhe more robusr studies evaluared the immunizarion of parients wirh srage IIIb and IV NSCLC with a liposomal for mulation of a MUCI pepride in hopes of improving the strength of rhe induced immune response. 22 A tor.al of 171 patienL5 were randomized to receive the vaccine wirh best supportive care (BSC) or BSC alone and were followed for clinical effecL5 as well as immunologic parameters. Although nor sraristically signifi cant, there was a 4.4-monrh median increase in OS for patients immunized with the vaccine versus those who received BSC (P = .112). In subgroup analysis, patients with stage IIIb locoregional disease demonsrrared rhe best responses because their median survival rime was unavailable ar rime of publication, compared with 13.3 months for BSC (P = .069). Such srudies have been viewed as encouraging because improvements in anrigen breadth and vaccination potency mighr achieve bener resulrs.
Komani er al conducred experiments in which patienL5 with NSCLC were vaccinared with DCs loaded wich MUC 1 peprides or tumor Iysare and evaluated for clinical outcome. 23 The investigators demonsrrared a survival advantage in vaccinated patienL5 whose rumors were found to express MUC1 compared with patients with MUC1-negative rumors (16.75 months vs. 3.8 months, respec tively; P= .0101) . Alchough rhe numbers of subjects are limited in this study, all of the patients who exhibited partial responses were vaccinated with peptides racher chan rumor lysare.
The observed increased porency of an epitope-focused ap proach over a vaccine consisting of the full-length antigen, ie, as part of the rumor lysate, is not a new concept and has been explored in murine models. 24 This advantage might stem from rhe isolarion of che perrinent epiropes of the antigen without di luting them wich immunologically irrelevant sequences. Vaccines incorporaring multiple epitopes from the same antigen produce strong immune responses ro each pepride in a codominant man ner insread of ro a single immunodominant pepride as can occur in vaccines using the full-length anrigen. Because some of che rargered antigens represenr oncogenes, rhere is a selecr advantage of including only shon segments of rhe gene racher dun rhe full length transcript wirh irs associared biologiC activity.
In the hopes of achieving better presentarion of antigens, researchers have soughr differenr mechanisms of delivering rhe vaccine ro APCs and modularing rhe milieu roward one rhar is more favorable for inducing immune responses. Morse et aI direcrly added anrigen to ex vivo-generared DCs via an engineered fowlpOX virus that expressed full-length CEA and 
The use of DNA-based vaccines has steadily increased after the initial Bnding of the ability ro induce gene expression after injec rion of naked DNA into the muscle of a mouse.27 Because of the increased concentration of DCs in the skin,28 increased velocity of CTL inducrion wich an intradermal roure veL5US an inrramus cular injection was demonstrared and argues for chat route of immunizarion using DNA-based srraregies. 29 Thompson et aI demonstrared the srrength ofa DNA approach chrough rhe injec tion of a DNA COUStrucr encoding 8 class I-resrricted epiropes in mice, resulting in rhe induction of a strong immune response ro each peptide wich the ability ro prorecr the mice from a challenge of rumor ceUs.3° In addition, the easily obtained consisrency in crearing multiple copies of a DNA vaccine, coupled with iL5 rela rive ease and low production cOSt compared wich ocher mechods, makes it a highly attractive mechod of vaccination.
Alchough the injection of naked DNA into mouse muscle resulrs in immune responses, several modifications were neces sary before che approach could be considered immunogenic. Construcring a DNA-based vaccine of epitopes in a "beads on a srring" mechod in which each pep ride is included sequentially in the rranslared prorein was made more porenr when defined spacer sequences were insrailed between epitopes. This merhod was furrher augmented ro the point where vaccination could result in rejection of esrablished rumors in mice rhrough the C terminus addition of an ubiquination signal.3 1 Multiple adjuvant agents have also been tested for their abil ity ro augmenr the efficacy of a DNA-based vacdne.3 2 These addirives tend to influence rhe cyroklne milieu, targer the DNA toward APCs, or prorecr the DNA from degradarion. Some of the more successful mechods include the addition of unmerh ylated oligonucleotides of alternating cyrosine and guanine residues, which interacr with roU-like receptors, fusion of heat shock protein-70 to the target protein, or addirion ~f genes Clinical Lung Cancer Vol 9 • Suppll February 2008 I S15 + +Immune re.,ponse., dici'ed; however. lhe authors do nor specify ",herhe, they were from paden" wlrh NSCLC.
+T,end roward improved rime to progression and overall survival. The route of vaccination has also been evaluared for irs ability to induce a strong immunity and seems to point tOward a paral lel berween immunogenicity and deposition of antigen in close proximiry to DCs. The higher quantiry of Langerhans cells in the dermis probably accounts for the seemingly gtearet immune response when a vaccine is given inuadetmally vetsus intrarnus cularly. 28 In facr, a merhod that uses a "tareoo" of genetic mate rial found gene expression within the dermis and resulted in the tejection of established tumotS in mice. 3 5 To date, there exists few clinical trials evaluating DNA-based vaccines, but srudies of the approach are beginning to be re ported. Early phase I studies have used the injection of naked DNA COntaining complete genetic sequences for gplOO or prostaric acid phosphatase fo r the evaluation ofsafery in patien tS with melanoma or prostate cancer, respectively.3 6 ,37 Although preliminary studies, both showed induction of specific immune responses withoUt achieving clinical effects.
DNA vaccination is not withour risk; however, the appar ent toxicities remain hypothetical because they have yet to be documented in mouse or hwnan experiments. There is a theoretical risk of the induction of anti-DNA antibodies akin to a lupus-like syndrome. In mice, it is possible to induce anri DNA antibodies, bur it requires mice with an unusual auroim mune phenotype, and the induced anribodies typically have different specificities than those found in patiems with lupus.3 8 Moreover, the constitutively active viral ptomoter used to dtive overexpression of the desired vaccine transcripr has rhe potencial to insert near a proto-oncogene with subsequent cellular trans formation. Thankfully this phenomenon has nor been observed clinically and remains a theoretical concern.
To dare, immunotherapy trials in NSCLC have shown safety and immune responses bur without significant therapeutic ef ficacy (Table 1) . [17] [18] [19] [20] [21] [22] [23] 25, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] In part, this is secondary to the fact that the majoriry of these studies are early phase UII clinical uials with small numbers of patients. Additionally, these trials are often uncontrolled experiments, and thus, all comparisons are made to historical conttols with the limitations that lie therein. Most importantly, the majoriry of the studies are immunizing patientS with Significant rumor burden and evaluating for rumOt regres sion. Active immunizarion might be more effeCtive in tumor ptevention or prevention of disease relapse rather than in actively vaccinating cancers in which standard chemotherapy has fuiled. Predominantly, these experiments have also rypically targeted Antigen Level' of Expression Currently, chemotherapy and radiation play an important role in rhe current rreatmenr straregies for most srages of NSCLC, wirh the sole exception in stage lA disease. It could be atgued thar sysremic chemotherapy and radiation would have negative effecrs on an anticancer immune tesponse through pervasive immunosuppressive effects. Indeed, it has been shown thar rhe number of prevaccinarion chemotherapeuric regimens is negatively correlated wirh T-cell responses. 52 Additionally, T-cell responses from a vaccine. improve with time afret the lasr cycle of chemotherapy, further providing evidence as to the negative effect chemotherapy has on tumor vaccines. There exisrs equipoise on rhis matrer, however, because the impact of chemotherapy was not seen in a mouse model, where peptide vaccinared mice were prorected from lerhal rumor cell chal lenges despite concurrent administration of cisplarin. 53 Indeed, there is a growing body of evidence thar chemother apy and radiation might have significanr benefits ro immuno therapy. In colon cancer, the use of cisplatin has been associared with increases in ICAM-l and fas expression with resultant increases in the level of fas-dependent and fas-independem cell killing, 54 In a mutine Lewis lung cancer model, the use of 1 dose of cisplatin augmented immunity, resulring in improved survival when rhe agem was given before vaccination. 55 Radia rion might also augment immune responses, as several patients with lung cancet have demonstrated upregulation offas, ICAM-I, and MHC class I expression alter rreatmem. 56 The immune enhancing effects of chemoradiarion are particularly important when COntemplating immunization in NSCLC as cisplatin and radiation are the standard of care for this disease.
To further elucidare the imporr.anr role chemotherapy might play in enhanCing immune responses, Nowak et al reported on a mouse model thar used the ligation of CD40 ro stimulare anticancer immunity.57 Mice given gemcitabine followed by the vaccine fared berrer than mice given rhe vaccine alone. How ever, administration of gemcitabine afrer the vaccine abrogated the immune response and tumor protection. This augmenting effect of gemcirabine was nor a result of debulking the rumor burden, as cohorts of mice who underwent partial resection of the rumor mass to the same size as the gemcitabine-rreared animals had lower survival rates when otherwise given identical rherapy. Thus, riming of the administrarion of chemotherapy might have imporrant effecrs on rhe development of an immune response after acrive immunizarion.
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Because gemcicabine is also a ftequently used chemotheta peutic agent for the [(eatment oflung cancet, mese observations might have clinical significance fOt tteating humans. Although me mechanism is not completely elucidated, me improvement in immune tesponses with chemothetapy might result from the processing of necrotic or apoprotic rumor cells by the draining lymph nodes. The vaccine men boostS this initial immunity induced via chemothetapy. In terms of translating these ob servations into the human experience, it would appear ro be advantageous to vaccinate patientS aftet usual metapy involving surgical resection followed by chemomerapy with cisplatinf gemcitabine and possibly ra&ition as indicated.
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In conclusion, rhe sheet number of parientS, coupled wirh a lack of curative merapy for most patienrs wim NSCLC, makes rhis cancer a necessary disease for the evaluation of new modali ties of treatment. The meoretical and somewhat proven ability to treat tumors, at least in mice, makes vaccination a promising memod mar one day might provide neW hope to mose afflicted.
The relative newness of the metapy and curtent lack of clini cal success indicates a continued need fOt experimentation. The exact selection of anrigens needed is unknown but will most likely require multiple epitopes of a diverse set of genes restrict ed ro multiple haplotypes to generate a vaccine that will combat me various tumor escape mechanisms. As new proteins are discovered in NSCLC and found to be immunogenic, research ers can begin to test meir suicability for inclusion in vaccines (Table 2) .58-80 Use of an epitope-focused approach takes advan tage of irs ability ro produce a strong, codominanr immunity toward each immunogenic peptide involved withour risking inclusion of the entire gene and its associated function. The roure and memod of vaccination is also debatable, but a DNA-based vaccine has many advantages. Although DCs and vital-based vectors have also shown strength and superiority over peptide and whole cell-based vaccines, DNA is not as labor intensive to use as DCs or as porentially tisky as viral vaccines. With DNA, there is neimer a need fOt prolonged culruring of cells nor concerns over neurralizing antibody responses.
Finally, the riming of the immunization to augment currenr srandard of care is an importanr issue. The rask of surveillance and, rhus, select removal of micrometastaric disease will be rested in patients after resection. Application of vaccines after chemotherapy and radiation mighr be a more effective method co enhance tumor-specific immunity.
The promise of an immunotherapy in cancer is a daunting challenge and one thar will hopefully live up to its porenrial. To create a vaccine thar will alter current morrality in NSCLC would be of gtear benefir to society as outcomes from rhis dis ease have not changed in more man 20 years.
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